Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALSUntangled does not recommend the Deanna Protocol for amyotrophic lateral sclerosis

Original source

Deanna ProtocolALSUntangled · 2 May 2013 (opens in a new tab)

ALSUntangled does not recommend the Deanna Protocol because there is no convincing objective evidence that it benefits people with amyotrophic lateral sclerosis (ALS). Anecdotal reports exist, but the protocol has not been shown to improve meaningful measures such as ALSFRS-R or forced vital capacity (FVC).

Why this matters

People with ALS and their clinicians should not consider the protocol an evidence-supported treatment based on the available review. More research would need to show reproducible biological effects and meaningful clinical benefits before it could be recommended.

Limitations and context

This is an independent expert review published in 2013, not a new clinical trial or primary research study. It notes anecdotal reports but does not provide convincing objective evidence of benefit. The review says further work is needed to assess both biological mechanisms and clinical outcomes.

Summarised by Compass 10 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?